Received Apr 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 42ZS4 | IM |
Incorrect Route of Administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 67-year-old female patient who received MMR (Priorix) (batch number 42ZS4) for prophylaxis. On 19-MAR-2025, the patient received Priorix (intramuscular). On 19-MAR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Incorrect Route of Administration). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 20-MAR-2025 Pharmacist called and reported recently received the MMR vaccine, the Priorix administered to patient at pharmacy intramuscularly instead of Subcutaneously, which led subcutaneous injection formulation administered by other route and just wondering if that dose has been studied that way or it has to be readministered. The reporter consented to follow up.